Published in Neuropsychopharmacology on November 18, 2009
Effects of Cannabidiol (CBD) on the Brain (CBD) | NCT04831294
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) (2011) 1.84
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry (2012) 1.77
Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev (2012) 1.67
Repeated Δ9-tetrahydrocannabinol exposure in adolescent monkeys: persistent effects selective for spatial working memory. Am J Psychiatry (2014) 1.44
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol (2010) 1.33
Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) (2013) 1.31
Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull (2013) 1.29
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci (2012) 1.15
Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry (2014) 1.14
Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology (2012) 1.13
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res (2013) 1.10
Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front Psychiatry (2013) 1.08
Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel) (2012) 1.02
Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci (2016) 1.01
Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans. Neuropsychopharmacology (2012) 1.01
Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol (2015) 1.01
Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. Psychol Med (2012) 1.00
Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A (2013) 1.00
How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull (2014) 0.98
Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci (2011) 0.94
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. Psychopharmacology (Berl) (2011) 0.92
Effects of cannabis on impulsivity: a systematic review of neuroimaging findings. Curr Pharm Des (2014) 0.92
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol (2014) 0.92
Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ(9) tetrahydrocannabinol. Br J Pharmacol (2013) 0.91
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov (2012) 0.91
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics (2015) 0.91
Cognitive function as an emerging treatment target for marijuana addiction. Exp Clin Psychopharmacol (2010) 0.90
Effects of Marijuana Use on Brain Structure and Function: Neuroimaging Findings from a Neurodevelopmental Perspective. Int Rev Neurobiol (2016) 0.90
Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) (2011) 0.90
Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology (2010) 0.89
Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction. Front Psychiatry (2013) 0.88
Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int J Neuropsychopharmacol (2014) 0.85
Impact of Cannabis Use on the Development of Psychotic Disorders. Curr Addict Rep (2014) 0.85
Animal models of cannabinoid reward. Br J Pharmacol (2010) 0.84
Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics (2015) 0.84
Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. J Psychopharmacol (2012) 0.84
Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS One (2012) 0.84
Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr Pharm Des (2012) 0.84
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol (2011) 0.83
The effect of cannabis use on memory function: an update. Subst Abuse Rehabil (2013) 0.83
Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol (2012) 0.82
Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway. J Neurosci (2016) 0.81
The role of cannabinoid 1 receptor expressing interneurons in behavior. Neurobiol Dis (2013) 0.81
Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiol Learn Mem (2013) 0.81
Neuroimaging evidence for cannabinoid modulation of cognition and affect in man. Front Behav Neurosci (2012) 0.81
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. Neuropsychopharmacology (2015) 0.81
Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans. Psychopharmacology (Berl) (2012) 0.81
A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol (2014) 0.81
Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology (2014) 0.81
Evaluation of Two Commercially Available Cannabidiol Formulations for Use in Electronic Cigarettes. Front Pharmacol (2016) 0.79
Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect. J Neural Transm (Vienna) (2011) 0.79
Cannabis use and cognitive functions in at-risk mental state and first episode psychosis. Psychopharmacology (Berl) (2013) 0.79
Cannabis Epidemiology: A Selective Review. Curr Pharm Des (2016) 0.79
Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry (2016) 0.78
Modulation of cognitive and emotional processing by cannabidiol: the role of the anterior cingulate cortex. Front Hum Neurosci (2013) 0.78
Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways. Br J Pharmacol (2011) 0.77
Cannabinoid Modulation of Frontolimbic Activation and Connectivity During Volitional Regulation of Negative Affect. Neuropsychopharmacology (2015) 0.76
A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol. Front Pharmacol (2017) 0.76
Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses. Psychopharmacology (Berl) (2016) 0.76
Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium. Genes Cancer (2012) 0.76
Assessing topographical orientation skills in cannabis users. ScientificWorldJournal (2012) 0.76
Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Front Pharmacol (2017) 0.76
An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol. Front Pharmacol (2017) 0.75
The effects of Δ(9)-tetrahydrocannabinol on the dopamine system. Nature (2016) 0.75
Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Front Pharmacol (2016) 0.75
Drug effects on responses to emotional facial expressions: recent findings. Behav Pharmacol (2015) 0.75
Δ(9)-Tetrahydrocannabinol decreases willingness to exert cognitive effort in male rats. J Psychiatry Neurosci (2017) 0.75
Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function. Front Pharmacol (2016) 0.75
Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks. Neurosci Biobehav Rev (2016) 0.75
Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend (2016) 0.75
Compromised External Validity: Federally Produced Cannabis Does Not Reflect Legal Markets. Sci Rep (2017) 0.75
A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial. PLoS One (2015) 0.75
Cannabis and development of dual diagnoses: A literature review. Am J Drug Alcohol Abuse (2016) 0.75
Clinical and Pre-Clinical Evidence for Functional Interactions of Cannabidiol and Δ(9)-Tetrahydrocannabinol. Neuropsychopharmacology (2017) 0.75
Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders. Front Pharmacol (2017) 0.75
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. Clin Psychopharmacol Neurosci (2017) 0.75
Evaluation of Oxidant/Antioxidant Status and Cytokine Levels in Patients with Cannabis Use Disorder. Clin Psychopharmacol Neurosci (2017) 0.75
Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Front Pharmacol (2017) 0.75
Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition. Curr Addict Rep (2017) 0.75
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat (1992) 29.45
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (2007) 11.27
A differential neural response in the human amygdala to fearful and happy facial expressions. Nature (1996) 5.94
Response and habituation of the human amygdala during visual processing of facial expression. Neuron (1996) 5.93
Adverse effects of cannabis. Lancet (1998) 4.58
Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks. Neuroimage (2001) 3.51
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Dissociation of object and spatial visual processing pathways in human extrastriate cortex. Proc Natl Acad Sci U S A (1991) 3.15
Cannabidiol--recent advances. Chem Biodivers (2007) 2.89
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology (2004) 2.87
Colored noise and computational inference in neurophysiological (fMRI) time series analysis: resampling methods in time and wavelet domains. Hum Brain Mapp (2001) 2.82
Functional neuroimaging of autobiographical memory. Trends Cogn Sci (2007) 2.51
Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A (1998) 2.48
Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology (2003) 2.37
Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med (1973) 2.31
Parallel striatal and hippocampal systems for landmarks and boundaries in spatial memory. Proc Natl Acad Sci U S A (2008) 2.27
Hearing and saying. The functional neuro-anatomy of auditory word processing. Brain (1996) 2.19
Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry (2005) 2.14
Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry (2009) 1.69
Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend (2006) 1.65
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr (2008) 1.61
Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) (1982) 1.56
Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci (2008) 1.55
The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci (2001) 1.50
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry (2008) 1.49
Role of prefrontal and anterior cingulate regions in decision-making processes shared by memory and nonmemory tasks. Cereb Cortex (2005) 1.47
Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci (2008) 1.44
Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry (2009) 1.40
Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology (2002) 1.29
Marijuana intoxication common experiences. Nature (1970) 1.27
Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol (1974) 1.25
Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry (2008) 1.24
Endocannabinoids and neuroprotection. Sci STKE (2002) 1.20
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis (2005) 1.19
Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol (2005) 1.17
Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol (1993) 1.16
Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology (2004) 1.10
Distinct roles for lateral and medial anterior prefrontal cortex in contextual recollection. J Neurophysiol (2005) 1.08
Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol (2006) 1.08
Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav Pharmacol (2005) 1.03
Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) (2008) 1.03
Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther (1976) 1.02
Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology (2004) 1.01
Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord (2005) 1.00
Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia (1973) 0.98
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry (2006) 9.44
Grand challenges in global mental health. Nature (2011) 8.40
Schizophrenia. Lancet (2009) 8.14
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry (2004) 5.95
Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry (2012) 5.45
Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet (2003) 4.91
Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry (2003) 4.84
Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry (2012) 4.54
The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 4.16
Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci (2009) 4.16
Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet (2012) 4.05
Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry (2002) 4.03
A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry (2002) 3.95
Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry (2009) 3.67
Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry (2002) 3.59
Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biol Psychiatry (2004) 3.36
Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry (2006) 3.35
A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol Psychiatry (2005) 3.15
Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry (2010) 3.05
Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet (2011) 2.99
Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron (2003) 2.99
Progressive increase of frontostriatal brain activation from childhood to adulthood during event-related tasks of cognitive control. Hum Brain Mapp (2006) 2.95
Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. Psychol Med (2006) 2.79
Symmetries in human brain language pathways correlate with verbal recall. Proc Natl Acad Sci U S A (2007) 2.78
Internet-enabled high-resolution brain mapping and virtual microscopy. Neuroimage (2007) 2.75
Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull (2006) 2.71
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry (2007) 2.53
Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry (2004) 2.44
Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. Nat Med (2005) 2.43
High-potency cannabis and the risk of psychosis. Br J Psychiatry (2009) 2.41
Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry (2012) 2.39
Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry (2011) 2.37
The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry (2012) 2.34
Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS One (2012) 2.33
Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res (2004) 2.30
Effect of long-term cannabis use on axonal fibre connectivity. Brain (2012) 2.27
The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations. Neurosci Biobehav Rev (2007) 2.25
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Report on the inaugural meeting of the International Consortium on Hallucination Research: a clinical and research update and 16 consensus-set goals for future research. Schizophr Bull (2012) 2.20
Dysconnectivity in schizophrenia: where are we now? Neurosci Biobehav Rev (2010) 2.16
Diffusion tensor imaging in schizophrenia. Biol Psychiatry (2005) 2.14
Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry (2003) 2.11
Amygdala, hippocampal and corpus callosum size following severe early institutional deprivation: the English and Romanian Adoptees study pilot. J Child Psychol Psychiatry (2009) 2.08
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry (2013) 2.06
Cannabis, the mind and society: the hash realities. Nat Rev Neurosci (2007) 1.99
Adolescents who were born very preterm have decreased brain volumes. Brain (2002) 1.97
Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry (2002) 1.96
Temporal course of auditory hallucinations. Br J Psychiatry (2004) 1.95
Reliability and comparability of psychosis patients' retrospective reports of childhood abuse. Schizophr Bull (2009) 1.94
White matter integrity and cognitive impairment in first-episode psychosis. Am J Psychiatry (2010) 1.92
Grey and white matter distribution in very preterm adolescents mediates neurodevelopmental outcome. Brain (2007) 1.91
Orbitofrontal cortex response to angry faces in men with histories of suicide attempts. Am J Psychiatry (2008) 1.90
Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch Gen Psychiatry (2004) 1.87
Salience network integrity predicts default mode network function after traumatic brain injury. Proc Natl Acad Sci U S A (2012) 1.86
Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder: computational morphometry study. Br J Psychiatry (2005) 1.83
Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. Schizophr Res (2011) 1.81
Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry (2006) 1.81
Tract-specific anisotropy measurements in diffusion tensor imaging. Psychiatry Res (2005) 1.79
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A (2012) 1.79
Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review. J Psychopharmacol (2007) 1.78
Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet (2002) 1.77
Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry (2013) 1.76
Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology (2005) 1.76
Measuring fMRI reliability with the intra-class correlation coefficient. Neuroimage (2008) 1.75
Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr Bull (2011) 1.72
Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry (2007) 1.72
Self-harm in first-episode psychosis. Br J Psychiatry (2008) 1.72
A diffusion tensor imaging study of fasciculi in schizophrenia. Am J Psychiatry (2007) 1.71
Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry (2008) 1.70
Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry (2010) 1.69
Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry (2009) 1.69
An automated method for the extraction of regional data from PET images. Psychiatry Res (2006) 1.67
Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev (2007) 1.67
Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev (2012) 1.67
TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J Virol (2010) 1.66
White matter microstructure in schizophrenia: effects of disorder, duration and medication. Br J Psychiatry (2009) 1.66
Separate brain regions code for salience vs. valence during reward prediction in humans. Hum Brain Mapp (2007) 1.64
Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry (2012) 1.64
The attenuated psychosis syndrome in DSM-5. Schizophr Res (2013) 1.61
Neural systems underlying British Sign Language and audio-visual English processing in native users. Brain (2002) 1.60
Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biol Psychiatry (2010) 1.60
Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One (2013) 1.59
Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives. Am J Med Genet B Neuropsychiatr Genet (2007) 1.59
A comparison of two delivery modalities of a mobile phone-based assessment for serious mental illness: native smartphone application vs text-messaging only implementations. J Med Internet Res (2013) 1.58
The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry (2012) 1.58
The phenomenology and neurobiology of delusion formation during psychosis onset: Jaspers, Truman symptoms, and aberrant salience. Schizophr Bull (2013) 1.58
Pathways to schizophrenia: the impact of environmental factors. Int J Neuropsychopharmacol (2004) 1.58